Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo

Abstract
Appel et al[1][1] reported in January that the paradigmatic KIT, PDGFR, ABL tyrosine kinase inhibitor imatinib mesylate (STI571/Gleevec), known to induce potent antitumor effects in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors, acts on nonmalignant hematopoietic cells,